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Abstract
Immune checkpoint inhibition leads to response in some patients with head and
neck squamous cell carcinoma (HNSCC). Robust biomarkers are lacking to date. We
analyzed viral status, gene expression signatures, mutational load and mutational
signatures in whole exome and RNA-sequencing data of the HNSCC TCGA dataset
(n = 496) and a validation set (DKTK MASTER cohort, n = 10). Public single-cell
gene expression data from 17 HPV-negative HNSCC were separately reanalyzed.
APOBEC3-associated TCW motif mutations but not total single nucleotide variant
burden were significantly associated with inflammation. This association was
restricted to HPV-negative HNSCC samples. An APOBEC-enriched, HPV-negative
subgroup was identified, that showed higher T-cell inflammation and immune
checkpoint expression, as well as expression of APOBEC3 genes. Mutations in
immune-evasion pathways were also enriched in these tumors. Analysis of single-
cell sequencing data identified expression of APOBEC3B and 3C genes in malignant
cells. We identified an APOBEC-enriched subgroup of HPV-negative HNSCC with
a distinct immunogenic phenotype, potentially mediating response to
immunotherapy.
K E YWORD S
immune checkpoint inhibition, head and neck cancer, APOBEC, mutational signature, tumor
inflammation
1 | INTRODUCTION
Cancer is a disease of the genome in that cancer cells have acquired
somatic variants that prove advantageous for their growth. These muta-
tions lead to changes in affected proteins and eventually cellular trans-
formation. Altered proteins can be recognized by the immune system
through presentation of peptides by the major histocompatibility com-
plex (MHC), which allows for eradication of the tumor. Immune evasion
is therefore considered one of the hallmarks of cancer.1 Immune check-
point inhibitors (ICI), improving immune recognition and T-cell activa-
tion, are an effective treatment option in a subgroup of patients in
several cancer types including head and neck squamous cell carcinoma
(HNSCC).2 The presence of an interferon-gamma inflamed gene expres-
sion signature (IFNG signature or T-cell inflamed phenotype3,4), expres-
sion of immune checkpoint PD-L12 and tumor mutational burden are
associated with response.5,6 However, effective predictive biomarkers
to guide ICI treatment in the clinic are lacking to date.
HNSCC is a common cancer type worldwide. It is mainly caused
by tobacco and alcohol consumption, as well as infection with the
human papilloma virus (HPV).7 These two groups (HPV-positive and
HPV-negative) are distinct entities with different outcome and differ-
ent tumor biology.8 A better responsiveness of HPV-associated
tumors to ICI has been suggested by early clinical data3 but not con-
firmed in other studies.2,9 Immune activation due to immunological
“foreignness” in virally induced cancers is a potential mechanism of
differential immune activation.10 Additionally, an intracellular antiviral
response mediated by the APOBEC3-family of proteins leads to the
accumulation of mutations and tumorigenesis.11 In several cancer
types, APOBEC-mediated tumorigenesis is increasingly recognized as
an important mechanism, even when independent of viral infec-
tions.12,13 APOBEC activity can be inferred from an analysis of muta-
tional signatures in the tumor genome. A so-called TCW motif has
been identified as an APOBEC-specific mutational signature.14 The
role of APOBEC-induced mutations in HPV-negative HNSCC and its
What's new?
Head and neck squamous cell carcinoma (HNSCC) is some-
times susceptible to immune checkpoint inhibitors, and bio-
markers are needed to help identify which tumors are most
likely to respond. Using the Cancer Genome Atlas, these
authors evaluated 496 HSNCCs by HPV status, gene expres-
sion signatures, mutational load, and mutational signatures.
They found that increased inflammation was associated with
APOBEC3-induced mutations in HPV-negative cancers. This
newly identified APOBEC-enriched, HPV-negative subgroup
showed higher immune checkpoint expression, and also
more mutations in immune-evasion pathways, suggesting
this may be a way to identify candidates for immune check-
point inhibitor therapy.
2 MESSERSCHMIDT ET AL.
association with immune activation is unclear. We analyzed muta-
tional signatures to uncover mechanisms driving tumor inflammation
in HNSCC.
2 | MATERIALS AND METHODS
2.1 | TCGA datasets
TCGA mutation data sets were downloaded for HNSCC15 (n = 502),
lung adenocarcinoma16 (LUAD, n = 542), urothelial bladder carci-
noma17 (BLCA, n = 395) and lung squamous cell carcinoma18 (LUSCC,
n = 178) from BROAD firehose in MAF format.
2.2 | Identification of an APOBEC-induced
subgroup and APOBEC mutational signature
Somatic mutation data in a MAF file was split into separate VCF files,
one per TCGA sample. To annotate putative APOBEC induced muta-
tions, we used the method described by Roberts et al,19 annotating
C>T and C>G variants in TCW (TCA, TCT) motifs and their reverse
complements, respectively. The number of cytosine mutations in the
TCW motif and outside of it in each sample were compared to the
respective occurrences of C/G and the TCW motif on chr1 of the
human genome with Fisher's exact test.
Values of P were subsequently Holm-Bonferroni corrected and all
cases with P0 < .05 were labeled APOBEC-enriched.
COSMIC single base substitution (SBS) signature contributions
for the mutational profile of each tumor sample were downloaded
from msignaturedb.20 Samples were grouped and a Wilcoxon rank
test was used to test for differences between groups.
2.3 | HPV status
HPV status was assigned based on the number of reads mapping to
HPV genomes, which are included as separate contigs in the bam files
(genome release 38) available from GDC Portal. We used a cutoff of
3500 reads to label a sample as HPV-positive. Results were checked
against the HPV expression signature described by Buitrago-Pérez et
al21 and a derived reduced signature containing only gene CDKN2A
and SYCP2 as well as prior results by Tang et al22 and TCGA clinical
annotation for consistency.
2.4 | Expression data analysis and IFNG signature
Expression data for sets of genes (“RNA Seq V2 RSEM”) was down-
loaded from the HNSCC TCGA provisional cohort15 from cbioPortal.
org.23 Samples that lacked either mutational or expression data were
excluded. The IFNG signature was computed as the mean of the log2-
transformed RSEM v2 expression values per sample.
2.5 | Identification of gene expression subtypes
HNSCC samples were attributed to gene expression subtypes. Basal,
Classical and Inflamed/Mesenchymal cluster centroids were down-
loaded from the supplementary material of Keck et al.8 Normalized
RSEM expression values from TCGA were log2-transformed and scaled.
The nearest centroid in terms of Euclidean distance was then assigned
as the label of a sample. To test for independence of variables between
Keck classes and APOBEC groups Fisher's exact test was used.
2.6 | Immune population metagene analysis
Gene expression signatures, also called metagenes, for tumor-infiltrat-
ing immune populations were acquired from The Cancer Immunome
Database24 (TCIA.at). Enrichment of signatures was computed for
each immune population in each sample with the R package GSVA
using the method gsva25. Differential metagene expression was
assessed with limma.26
2.7 | Analysis of immunotherapy-essential genes
We analyzed mutations in 554 genes which have been shown to be
essential for cancer immunotherapy in a CRISPR assay.27 To identify
enrichment of mutations in these genes, we used a Fisher exact test
considering the number of cases in HPV-negative/APOBEC-enriched
and HPV-negative/APOBEC-negative respectively, and the number of
mutated genes from the aforementioned gene set in each group. Vari-
ant effect was annotated with Jannovar.28
2.8 | Analysis of APOBEC timing
Variant allele fractions (VAF) of TCW mutations compared to all other
variants were used to infer the timing of APOBEC activity. Patients
harboring significantly distinct variant allele fractions for TCW vari-
ants compared to all other variants of a given case were classified as
early APOBEC activation, if the TCW variants had higher VAF, or as
late activation, if they had lower overall VAF compared to all other
variants. Patients with no difference or too few variants were grouped
as “no preference”. The false-positive rate was controlled with the R
package q value,29 using a threshold of 0.2.
2.9 | Single-cell expression
This analysis was based on the digital expression matrix, holding the
expression values of 23 686 genes for 5902 cells of 17 tumor samples
(GSE103322), together with a classification into malignant and various
nonmalignant cell types provided by the authors.30 Data were projec-
ted into tSNE coordinates using the standard Seurat workflow31 and
visualized using feature plots and violin plots.
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2.10 | Independent validation of IFNG signature
scores
Patients with advanced cancers, an ECOG performance status of 0–1
and an age < 50 years were eligible for enrollment in the DKTK-MAS-
TER program across cancer centers in Germany. The DKTK-MASTER
trial was approved by local ethics committees (Heidelberg and Berlin).
Written informed consent was obtained from all participating patients.
Whole-exome and RNA sequencing were performed on fresh-frozen
tissues. From RNA-seq data for all cases, HPV status was predicted as
described above. IFNG signature was computed as described above
after generating transcript abundances with salmon32 against
ENSEMBL v75. The mapping of gene symbols used and their respec-
tive ENSEMBL ids are shown in Table S1.
3 | RESULTS
3.1 | Identification of inflammation-associated
mutational signatures
Mutation and gene expression data from head and neck squamous cell
carcinoma samples were downloaded from The Cancer Genome Atlas
(n = 496). The presence of a T-cell inflamed microenvironment was
F IGURE 1 Inflammation as measured by an Interferon-gamma signature score is associated with APOBEC activity, not total variant count. A,
Relationship between total single nucleotide variant count and the six-gene IFNG signature. No significant correlation was found between these
measures (R = −0.03 ± 0.08). B, Relationship between the six-gene IFNG signature and the number of C>T and C>G mutations in TCW motifs.
Colors indicate HPV-status (red: HPV-negative, n = 432, blue: HPV-positive, n = 64). A significant correlation between TCW mutations and the
IFNG signature was identified in HPV negative cases (R = 0.18, P = 1 × 10−4). C, The frequency of base exchange motifs (eg, C>A substitution
with incorporation of the bases at the 50 and 30 end, thus allowing 96 potential mutation types) was compared between the patients with the
highest and lowest IFNG signature within the TCGA cohort. The top 20% of inflamed cases showed a significant enrichment of variants in the
APOBEC3-associated TCW context (*P < .05, **P < .01, all P values were Bonferroni corrected) [Color figure can be viewed at
wileyonlinelibrary.com]
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assessed in the samples by analysis of a six-gene IFNG signature.33
Total count of single nucleotide variants (SNV) did not correlate signif-
icantly with the IFNG signature (Figure 1A). Next, we analyzed associ-
ations between the T-cell inflamed gene expression phenotype and
mutational signatures. C>T and C>G mutations are referred to as
TCW mutations, as they preferentially occur in TCA and TCT contexts
(TCW motif), indicating APOBEC3-induced mutagenesis. TCW muta-
tions were significantly enriched in patients with high expression of
the IFNG signature (Figure 1C).
3.2 | Analysis of HPV-status on inflammation and
mutational signatures
HNSCC consists of biologically distinct HPV-positive and -negative
subgroups. We identified 64 HPV-positive (53 HPV16, 8 HPV33 and
3 HPV35) and 432 HPV-negative samples in the TCGA dataset.
IFNG signature score, total SNV count, counts of TCW mutations
and the ratio of the number of TCW mutations compared to the num-
ber of total mutations (TCW ratio) were assessed in both groups.
Mutational load was significantly more pronounced in HPV-negative
samples than in HPV-positive (Figure 2A, P = 1.7 × 10−4), whereas the
IFNG signature was significantly higher in HPV-positive samples (Fig-
ure 2B, P = 3.7 × 10−5). Further, we compared the ratio of the number
of TCW mutations/number of total mutations as a surrogate measure
for APOBEC3 mutational activity, which was significantly higher in
HPV-positive tumors (Figure 2C, P = 2.6 × 10−3). We then analyzed
the association between TCW mutations and inflammation in HPV-
positive and HPV-negative HNSCC and found a significant correlation
only among HPV-negative HNSCC (Figure 1B). An association
between APOBEC-induced TCW-mutations and the IFNG signature
could be validated in independent LSCC, LUAD and BLCA datasets
(Figure S1).
3.3 | Identification of an APOBEC-enriched HPV-
negative subgroup
Since the association between APOBEC-induced mutations (TCW
mutations) and the T-cell inflamed phenotype was restricted to HPV-
negative samples, we grouped the HPV-negative samples into
APOBEC-enriched (n = 84) and APOBEC-negative (n = 348) cases. This
newly defined HPV-negative, APOBEC-enriched subgroup showed a
higher relative contribution for both APOBEC-associated mutational
Signatures 2 and 13 (Figure S2A). Further, the scores of Signatures 2
and 13 ranked higher in the APOBEC-enriched group when compared
among the other COSMIC SBS signatures per sample (Figure S2B).
We observed that the HPV-negative subgroup with an enrich-
ment of APOBEC-induced mutations showed a significantly higher
IFNG signature score compared to all other HPV-negative cases
(HPV-negative, APOBEC-negative; Figure 3A). To exclude the possi-
bility that this signal came from samples falsely classified as HPV-neg-
ative, we repeated the analysis by removing all HPV-negative cases
with more than five reads mapping to any of the HPV contigs without
a change in results (Figure S4).
In addition to differences observed regarding overall inflammation,
HPV-negative, APOBEC-enriched cases also exhibited higher predicted
infiltration of myeloid-derived suppressor cells (MDSC), Type 17T-
helper cell and effector memory CD8+-cell gene expression signatures
(Figure S5). Further, differential expression of immune checkpoints was
analyzed between groups. A significantly higher gene expression was
identified for CD274 (PD-L1), CTLA4, LAG3 and PDCD1 (PD-1) in
APOBEC-enriched cases. Only VTCN1 showed a significantly lower
gene expression in APOBEC-enriched cases (Figure 3B).
Previous analyses have established different HNSCC subgroups
based on gene expression.8 The APOBEC-enriched HPV-negative
samples were assigned to these subgroups and were significantly
enriched in the inflamed/mesenchymal cluster (Table S2).
F IGURE 2 HPV status is an important variable in HNSCC. A, Boxplot of total single nucleotide variant count, grouped by HPV status. Total
single nucleotide variant count was significantly higher in HPV-negative cases (P = 1.7 × 10−4). B, Boxplot of INFG signature score, grouped by
HPV status. The six-gene IFNG signature score was significantly higher in HPV-positive samples (P = 3.7 × 10−5). C, Boxplot of ratio of TCW
variants to total single nucleotide variant count, grouped by HPV status. The TCW-ratio was significantly higher in HPV-positive samples
(P = 2.6 × 10−3)
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We additionally analyzed mutations in immunotherapy-relevant
genes.27 The APOBEC-enriched subgroup showed significantly more
variants with functional impact in immunotherapy-essential genes
(Table 1, P = 1.8 × 10−4). Among those genes, HLA-A showed the
highest relative enrichment among APOBEC-enriched cases and
remained significant after correcting for multiple testing (Table S3).
Among HPV-negative samples, smokers were significantly under-
represented (P = .02, Table S4) in the APOBEC-enriched group, no sig-
nificant differences were observed for alcohol consumption. Further,
we observe nonrandom associations between tumor site and HPV/
APOBEC group (P < .05, Table S5) with an enrichment of APOBEC-
associated cases in tumor arising from the oral cavity and alveolar
ridge but an underrepresentation of laryngeal tumors and tumors of
the oral tongue. No difference in overall survival was identified
between HPV-negative APOBEC-enriched and APOBEC-negative
groups (Figure S3).
F IGURE 3 HPV-negative, APOBEC-enriched tumors exhibit
higher inflammation, higher immune checkpoint expression. A, IFNG
signature scores, grouped by HPV status and APOBEC enrichment for
HPV-negative cases. HPV negative, APOBEC-enriched HNSCC
showed a significantly higher IFNG signature than APOBEC-negative
samples (P = 1.5 × 10−4). No significant difference between HPV-
positive and HPV-negative/APOBEC-enriched samples was found. B,
Gene expression of five immune checkpoints was significantly
different between APOBEC-enriched and APOBEC-negative HPV-
negative samples (P0 < .05 after Benjamini-Hochberg correction). All
but VTCN1 showed significantly higher expression among APOBEC-
enriched cases [Color figure can be viewed at wileyonlinelibrary.com]
TABLE 1 HPV-negative APOBEC-enriched and APOBEC-negative groups with counts of hits in gene set identified by Patel et al
HPV-negative/APOBEC-enriched HPV-negative/APOBEC-negative P value
No. of cases 84 348
No. of hits (collapsed to genes)/No. of cases 7.6 (638 total) 4.7 (1643 total) 1.8E−4
No. of hits with functional impact (collapsed to
genes)/No. of cases
5.7 (476 total) 3.7 (1277 total) 8.8E−4
No. of hits (collapsed to genes), without HLA genes/
No. of cases
7.3 (617 total) 4.7 (1623 total) 4.1E−4
No. of hits with functional impact (collapsed to
genes), without HLA genes/No. of cases
5.5 (461 total) 3.6 (1259 total) 1.6E−3
Note: Two sets of Fisher exact tests were carried out, first considering a gene mutated if any variant was found. Second, only mutations with putative func-
tional impact (MODERATE, HIGH flags as returned by Jannovar, eg, missense or stop gain variants) were considered. Both times, the APOBEC-enriched
group showed a significant enrichment for mutations in immunotherapy related genes compared to the APOBEC-negative group. Tests were re-done with-
out variants in HLA genes to exclude possible false-positive calls from variant calling.
F IGURE 4 Cases with early APOBEC-activation show higher
inflammation. IFNG signature score in HPV-negative cases for each
group of APOBEC3 activity timing. n (APOBEC early) = 15, n
(APOBEC late) = 50, n (no preference) = 367
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3.4 | APOBEC activation is an early event in some
HNSCC
To identify temporal patterns of APOBEC activation during tumor
evolution, we analyzed the variant allele frequency (VAF) of TCW
mutations in HNSCC. Cases with early TCW variants exhibited a sig-
nificantly higher IFNG signature score compared to late TCW activa-
tion (Figure 4). We repeated the analysis for the TCGA cohorts of
BLCA and LUAD. For BLCA, we did not observe any difference
between the groups. However, in LUAD, we observed the opposite
effect. Cases with early APOBEC activation were found to exhibit
lower inflammation scores than the other two groups, which has been
described before34 (Figure S6).
3.5 | Identification of APOBEC3B and APOBEC3C
expression in HNSCC
Gene expression of APOBEC3 family genes was analyzed in the TCGA
cohort. HPV-positive samples exhibited significantly higher total
APOBEC3 gene expression than HPV-negative samples (Figure 5A).
Among HPV-negative samples, the APOBEC-enriched subgroup
showed significantly higher expression of APOBEC genes than the
APOBEC-negative subgroup. When analyzing APOBEC gene expres-
sion by gene, APOBEC3A was most prominently overexpressed in
HPV-negative, APOBEC-enriched samples (Figure S7). Since bulk gene
expression analyses do not differentiate between tumor and stroma,
we analyzed gene expression data in single-cell transcriptome data of
HPV-negative HNSCC30 (GSE103322).
F IGURE 5 Independent single-cell expression data demonstrates the expression of APOBEC3C and APOBEC3B in tumor cells. A, Aggregated
expression of APOBEC3 family genes for the three groups HPV-positive, HPV-negative/APOBEC-enriched, HPV-negative/APOBEC-negative.
HPV-positive cases show significantly higher APOBEC3 expression than HPV-negative cases. Among those, the APOBEC-enriched subgroup
exhibits significantly higher APOBEC3 gene expression. B, tSNE projection of all cells from 17 single-cell transcriptomics-profiled cases,30
grouped into cell types. C, Violin plots of APOBEC3 gene expression between malignant (red) and nonmalignant cells (blue). APOBEC3B and
APOBEC3C gene expression were detected in tumor cells. D, tSNE plots with projected expression of genes in the APOBEC3 family in 17 single-
cell data sets of HPV-negative cases.30 Biomarker-based groups of malignant (red) and nonmalignant cells (blue). Expression strength indicated by
color intensity, with gray indicating that no expression was detected [Color figure can be viewed at wileyonlinelibrary.com]
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Among those, APOBEC3B and APOBEC3C gene expression were
highest in malignant cells (Figure 5B-D).
3.6 | Independent validation of findings
In an independent cohort of 10 HPV-negative cases of HNSCC,
sequenced for the DKTK MASTER program from six cancer centers in
Germany, we set out to validate these findings. We identified one
HPV-negative patient with an APOBEC-enriched mutational signa-
ture. Again, we computed the IFNG signature score and compared it
between the already defined groups (Figure 6). The HPV-negative
case with APOBEC enrichment (Figure S8, data available in Table S6)
showed the highest inflammation in this cohort.
4 | DISCUSSION
Immune checkpoint inhibition has become an important treatment
option in HNSCC, providing a benefit in a subset of patients.35 The
predictive value of a T-cell inflamed phenotype, as defined by an IFNG
expression signature, has been shown in HNSCC and other tumor
types.3,4 Additionally, a high mutational load is correlated with
response to immune checkpoint inhibition.5 Yet, in our and other ana-
lyses, no clinically useful correlation between those two predictive
markers was shown.6
To better understand differential immune activation and evasion in
HNSCC, we analyzed the relationship between different mutational sig-
natures and inflammation in HNSCC. An APOBEC-induced TCW muta-
tional signature was significantly associated with a T-cell inflamed
phenotype. This association could be validated in other tumor types,
including lung and bladder cancer. Previous studies also support the
role of APOBEC-induced mutational signatures in immune activation in
several cancer types.36,37 Among tumors with a high APOBEC muta-
tional burden, Faden et al described HNSCC to have the highest IFNG
levels, especially among HPV-positive cases.38 In addition to these ana-
lyses, we show that, despite overall high levels of inflammation and
APOBEC mutagenesis in HPV-positive HNSCC, a dose-dependent
association between TCW mutations and inflammation is restricted to
HPV-negative cases, thus leading to the establishment of an APOBEC-
associated subgroup with differential immune activation among HPV-
negative samples. We attribute the difference between HPV-positive
and HPV-negative cases to the overall high impact of APOBEC-induced
tumorigenesis in HPV-positive HNSCC11 and a generally higher level of
IFNG activation in these tumors. The activation of APOBEC in non-
virally associated tumors has also been shown across cancer types.14
This signature has been proposed to occur later in tumorigenesis and to
induce branched evolution in lung cancer.34,39
Our own analyses in HNSCC rather suggest an early APOBEC
activation in a subset of HPV-negative HNSCC with an immunogenic
phenotype, thus proposing a different oncogenic mechanism in
HNSCC, further supporting the idea of a distinct subgroup. It is cur-
rently unclear what drives this APOBEC activation. Previous analyses
have suggested a link with single strand exposure and DNA repair
defects.40,41 It is also conceivable that short-term viral exposure
induces APOBEC activation and carcinogenesis without genomic viral
integration in some patients. Faden et al also suggested a potential
role of germline APOBEC polymorphisms in mutagenesis.38
A subgroup of HPV-negative oral squamous cell carcinoma patients
in never-smokers, never-drinkers with high tumor inflammation has
been described in the literature.42 This agrees with our observation,
since smokers were underrepresented in the APOBEC-associated sub-
group that was also enriched for tumors arising from the oral cavity.
Further research focusing on the impact of short-term viral exposure
and APOBEC-activation or virus-independent mechanisms of APOBEC-
activation, especially in this hard-to-treat subgroup, are of interest.
We were not able to immunohistochemically analyze APOBEC
protein expression in HNSCC and HNSCC patient-derived xenograft
models, a well-known problem with currently available APOBEC3
antibodies.12 In the TCGA data, APOBEC3A was most prominently
expressed in the APOBEC-enriched subgroup. However, the tumor
microenvironment poses a challenge in the analysis of bulk data.
Inflammatory signatures, such as the IFNG signature, are associated
with more immune infiltration and lower tumor purity. We therefore
resorted to a re-analysis of publicly available single-cell gene expres-
sion data. Doing so, we were able to circumvent the bias of measuring
APOBEC3 activity in the tumor microenvironment.43 Here, expression
of APOBEC3 subtypes 3B and 3C was most prominent among malig-
nant cells. APOBEC3B has also been identified in previous publica-
tions on APOBEC activation in cancer, including HNSCC,13,37 whereas
the role of APOBEC3C remains less well defined. Since transient
expression of APOBEC3 subtypes has been described,44 short term
activity of other APOBEC3-subtypes might cause mutations in the
absence of APOBEC gene expression in later analyses, thus poten-
tially explaining the observed differences. The observed different
F IGURE 6 Independent analysis in a clinical cohort. IFNG
signature score in the head-and-neck DKTK Master cohort grouped
by APOBEC status for all HPV-negative cases. The only identified
HPV-negative/APOBEC-enriched sample harbored the highest IFNG
gene expression signature score
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contributions of APOBEC mutational Signatures 2 and 13 between
HPV-positive and HPV-negative samples might also reflect different
underlying APOBEC3-activity.
It is currently unclear what causes the T-cell inflamed phenotype
in APOBEC-induced cancers. We were able to show that these
tumors, despite harboring the same overall mutational load, show a
distinct immune escape, represented by an enrichment for mutations
in immunotherapy-essential genes (such as HLA-A), expression of reg-
ulatory immune signatures, including myeloid-derived, as well as
expression of immune checkpoint molecules. Furthermore, these sam-
ples cluster in the immunogenic mesenchymal/inflamed subgroup.8 It
is possible that APOBEC-induced mutations are more prone to detec-
tion by the immune system, due to their association with viral infec-
tions. Yet, our own analyses in APOBEC-induced cancers did not
show an increase in bioinformatically predicted neo-antigens (data not
shown). Therefore, the reasons for the different mechanisms of
immune evasion in APOBEC-associated HPV-negative HNSCC are
not known but might also be relevant in other tumor types including
urothelial45,46 or lung cancer.37 Does APOBEC-activity translate into
differential response to immune checkpoint inhibition? Early studies
suggest that APOBEC-associated tumors might indeed respond better
to ICI therapy.37,47 We were able to find some supporting evidence
for the differential immune activation also within the recurrent/meta-
static DKTK-MASTER cohort. However, this cohort is small and does
not represent the demographics of the majority of HNSCC patients.
Thus, further research is required to analyze this association, espe-
cially in patient cohorts treated with immune checkpoint inhibition.
Mutational signatures inferred from DNA sequencing and specifically
APOBEC3-associated motifs should be further investigated as a
potentially predictive biomarker for immune checkpoint inhibition in
HPV-negative HNSCC.
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